BR112016023025A2 - direcionamento de câncer de mama her2+ resistente a trastuzumab com uma nanopartícula de direcionamento de her3 - Google Patents

direcionamento de câncer de mama her2+ resistente a trastuzumab com uma nanopartícula de direcionamento de her3

Info

Publication number
BR112016023025A2
BR112016023025A2 BR112016023025-6A BR112016023025A BR112016023025A2 BR 112016023025 A2 BR112016023025 A2 BR 112016023025A2 BR 112016023025 A BR112016023025 A BR 112016023025A BR 112016023025 A2 BR112016023025 A2 BR 112016023025A2
Authority
BR
Brazil
Prior art keywords
her2
molecule
resistant
patient
breast cancer
Prior art date
Application number
BR112016023025-6A
Other languages
English (en)
Inventor
K. MEDINA-KAUWE Lali
SIMS Jessica
Taguaim Michael
Hanson Chris
CUI Xiaojiang
Original Assignee
Cedars-Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars-Sinai Medical Center filed Critical Cedars-Sinai Medical Center
Publication of BR112016023025A2 publication Critical patent/BR112016023025A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

são divulgados, neste documento, métodos de tratamento de câncer em um paciente, o método compreendendo a identificação de um paciente que é resistente ao tratamento com uma terapia com anti-her2; e a administração ao paciente de uma molécula de distribuição de droga, que compreende uma molécula de polipeptídeo adaptado para visar e/ou penetrar em um tipo de célula; uma molécula de ácido nucleico ligado à sequência de polipeptídeo através de interações eletrostáticas; e um agente químico ligado não covalentemente à sequência de ácido nucleico. também são divulgados métodos para induzir apoptose em uma célula de câncer de mama her2+ resistente à terapia com anti-her2, o método compreendendo o contato da célula de câncer de mama her2+ resistente à terapia com anti-her2 com a molécula de distribuição de droga. além disso são divulgados, neste documento, métodos de tratamento de câncer em um paciente, o método compreendendo a identificação de um paciente que seja resistente à terapia com anti-her2; e a administração ao paciente de uma quantidade terapeuticamente eficaz de uma molécula de distribuição de droga, que compreende uma molécula de polipeptídeo adaptada para visar e/ou penetrar em um tipo de célula; e uma molécula de corrol sulfonada ligada à sequência de polipeptídeo. finalmente são divulgados, neste documento, métodos para induzir apoptose em uma célula de câncer de mama her2+ resistente à terapia com anti-her2, o método compreendendo o contato da célula de câncer de mama her2+ resistente à terapia com anti-her2 com uma molécula de distribuição de droga, que compreende uma molécula de polipeptídeo adaptada para visar e/ou penetrar em um tipo de célula; e uma molécula de corrol sulfonada ligada à sequência de polipeptídeo.
BR112016023025-6A 2014-04-04 2015-04-04 direcionamento de câncer de mama her2+ resistente a trastuzumab com uma nanopartícula de direcionamento de her3 BR112016023025A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461975687P 2014-04-04 2014-04-04
US61/975,687 2014-04-04
PCT/US2015/024400 WO2015154059A2 (en) 2014-04-04 2015-04-04 Targeting trastuzumab-resistant her2+breast cancer with a her3-targeting nanoparticle

Publications (1)

Publication Number Publication Date
BR112016023025A2 true BR112016023025A2 (pt) 2018-01-16

Family

ID=54241451

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016023025-6A BR112016023025A2 (pt) 2014-04-04 2015-04-04 direcionamento de câncer de mama her2+ resistente a trastuzumab com uma nanopartícula de direcionamento de her3

Country Status (13)

Country Link
US (2) US9850293B2 (pt)
EP (1) EP3129066B1 (pt)
JP (2) JP6728056B2 (pt)
KR (1) KR20160141751A (pt)
CN (1) CN106170305A (pt)
AU (1) AU2015240460A1 (pt)
BR (1) BR112016023025A2 (pt)
CA (1) CA2943297A1 (pt)
IL (1) IL248046B (pt)
MX (1) MX2016013025A (pt)
RU (1) RU2692104C2 (pt)
WO (1) WO2015154059A2 (pt)
ZA (1) ZA201607375B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9078927B2 (en) * 2007-07-06 2015-07-14 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
MX366347B (es) * 2012-08-03 2019-07-05 Cedars Sinai Medical Center Aislamiento de mutantes mejoradores del trafico de la proteina de administracion de farmaco.
CN105307499B (zh) * 2013-05-08 2018-04-27 西塞医疗中心 用于肿瘤毒性和mri的靶向可咯
BR112016016202A2 (pt) 2014-01-17 2017-09-19 Cedars Sinai Medical Center Construtos de direcionamento de receptores e uso dos mesmos
WO2015154059A2 (en) 2014-04-04 2015-10-08 Cedars-Sinai Medical Center Targeting trastuzumab-resistant her2+breast cancer with a her3-targeting nanoparticle
CN109475636A (zh) * 2016-05-27 2019-03-15 席德-西奈医疗中心 药物-递送纳米颗粒和耐药癌症的治疗
CN106474472B (zh) * 2016-10-11 2021-06-08 连云港市第一人民医院 肿瘤曲妥珠单抗靶向anti-miR-21纳米粒子及其制备方法
US20210077575A1 (en) * 2018-01-02 2021-03-18 Cedars-Sinai Medical Center Nanoparticles for the targeted delivery of therapeutic polypeptides
JP2022518139A (ja) * 2019-01-03 2022-03-14 キム・ソンチョン ｐＨ依存的膜透過性ペプチドを用いた薬物運搬体、及びそれと薬物の複合体
KR102182985B1 (ko) * 2019-01-03 2020-11-26 주식회사 바이오이즈 pH 의존적 막 투과성 펩타이드를 이용한 약물 운반체 및 그것과 약물의 복합체

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391723A (en) 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
CA2391534A1 (en) 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
US6855135B2 (en) 2000-11-29 2005-02-15 Hill-Rom Services, Inc. Vacuum therapy and cleansing dressing for wounds
WO2002062823A2 (en) 2001-02-02 2002-08-15 Yale University Peptides for facilitating composite receptor expression and translocation of macromolecules
WO2002094318A1 (en) 2001-05-18 2002-11-28 University Of Southern California Vector for targeted delivery to cells
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
JP2004024724A (ja) 2002-06-28 2004-01-29 Biopol Co Ltd 多層構造の微細多孔性フォームドレッシング材及びその製造方法
US7329638B2 (en) 2003-04-30 2008-02-12 The Regents Of The University Of Michigan Drug delivery compositions
US7205387B2 (en) 2003-08-28 2007-04-17 Agency For Science, Technology And Research Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist
TWI355894B (en) 2003-12-19 2012-01-11 Du Pont Herbicidal pyrimidines
WO2005117928A1 (en) 2004-05-30 2005-12-15 Cemines, Inc. Compositions and methods for the treatment of skin cancer
US8057821B2 (en) 2004-11-03 2011-11-15 Egen, Inc. Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
US20110052697A1 (en) 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
US9078927B2 (en) 2007-07-06 2015-07-14 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
WO2009151539A1 (en) 2008-05-24 2009-12-17 Sirnaomics, Inc. COMPOSITIONS AND METHODS USING siRNA MOLECULES FOR TREATMENT OF GLIOMAS
WO2010078517A2 (en) 2008-12-31 2010-07-08 Sirnaomics, Inc. Compositions and methods using sirna molecules and sirna cocktails for the treatment of breast cancer
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
CA2772660A1 (en) 2009-09-01 2011-03-10 Northwestern University Delivery of therapeutic agents using oligonucleotide-modified nanoparticles as carriers
US20130065778A1 (en) * 2010-01-26 2013-03-14 Yale University MicroRNA Signatures Predicting Responsiveness To Anti-HER2 Therapy
MX2014014266A (es) 2012-05-22 2015-06-23 Smith & Nephew Aparatos y metodos para terapia de heridas.
MX366347B (es) 2012-08-03 2019-07-05 Cedars Sinai Medical Center Aislamiento de mutantes mejoradores del trafico de la proteina de administracion de farmaco.
CN105307499B (zh) 2013-05-08 2018-04-27 西塞医疗中心 用于肿瘤毒性和mri的靶向可咯
BR112016016202A2 (pt) 2014-01-17 2017-09-19 Cedars Sinai Medical Center Construtos de direcionamento de receptores e uso dos mesmos
WO2015154059A2 (en) 2014-04-04 2015-10-08 Cedars-Sinai Medical Center Targeting trastuzumab-resistant her2+breast cancer with a her3-targeting nanoparticle
CA2959492A1 (en) 2014-08-27 2016-03-03 Thomas Primiano Anti-tumor compositions and methods

Also Published As

Publication number Publication date
EP3129066A2 (en) 2017-02-15
JP2020176123A (ja) 2020-10-29
WO2015154059A3 (en) 2015-11-19
IL248046B (en) 2020-07-30
RU2016140214A (ru) 2018-05-08
US20160060316A1 (en) 2016-03-03
JP6728056B2 (ja) 2020-07-22
ZA201607375B (en) 2018-11-28
CA2943297A1 (en) 2015-10-08
CN106170305A (zh) 2016-11-30
RU2692104C2 (ru) 2019-06-21
EP3129066A4 (en) 2017-09-20
IL248046A0 (en) 2016-11-30
AU2015240460A1 (en) 2016-09-15
JP2017514800A (ja) 2017-06-08
MX2016013025A (es) 2017-04-27
US9850293B2 (en) 2017-12-26
WO2015154059A2 (en) 2015-10-08
EP3129066B1 (en) 2020-08-12
US20180066033A1 (en) 2018-03-08
KR20160141751A (ko) 2016-12-09
RU2016140214A3 (pt) 2018-11-23

Similar Documents

Publication Publication Date Title
BR112016023025A2 (pt) direcionamento de câncer de mama her2+ resistente a trastuzumab com uma nanopartícula de direcionamento de her3
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
MX2020004948A (es) Receptor de antígeno quimérico que selecciona como diana bcma, receptor de antígeno quimérico que selecciona como diana cd19 y terapias de combinación.
BR112017023269A2 (pt) métodos para tratamento de câncer
BR112018005837A2 (pt) anticorpo anti-mesotelina, ácido nucleico, vetor, célula hospedeira, método de preparação do anticorpo e composição farmacêutica
BR112017000703A2 (pt) métodos para tratar ou retardar a progressão do câncer, para reduzir ou inibir a reincidência do câncer, para tratar ou retardar a progressão da imunidade tumoral e para aumentar, intensificar ou estimular uma resposta ou função imune e kit
BR112016026197A2 (pt) anticorpos anti-b7-h1 e anti-ctla-4 para o tratamento de câncer de pulmão de não pequenas células
BR112018008503A2 (pt) método para tratar câncer de pulmão de células pequenas, método para tratar um sujeito, método para selecionar um sujeito com câncer
BR112016002000A2 (pt) Diagnóstico e terapia de câncer envolvendo células-tronco tumorais
BR112015006176A8 (pt) método de tratamento de câncer em um indivíduo com necessidade de tratamento
ECSP15005280A (es) Agentes de unión de proteína de r-espondina humana (rspo3) y usos de los mismos
EA201691023A1 (ru) Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
EA201890272A1 (ru) Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака
BR112016012713A2 (pt) Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento
BR112014021101A2 (pt) Anticorpo, composição farmacêutica, droga de combinação, dna e método de tratamento e/ou prevenção de câncer, uso de um anticorpo
CO2019005466A2 (es) Crenolanib para tratar mutaciones asociadas con trastornos proliferativos con flt3 mutado
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
BR112017014793A2 (pt) regime de dosagem para antagonistas de madcam
BR112016028641A2 (pt) ?método para tratar câncer?
BR112014027905A2 (pt) anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico.
BR112018075660A2 (pt) métodos de tratamento de câncer de pâncreas
BR102014029197A8 (pt) conjugado, seu processo de obtenção, uso, composição farmacêutica, ácido nucléico, vetor e célula hospedeira.
MX2017016183A (es) Vacuna de adn que dirige vegfr-2 para terapia de combinacion.

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Ipc: A61K 47/00 (2006.01), A61P 35/00 (2006.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements